Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment Naïve primary prostate cancer

Daniel E. Spratt*, Mohammed Alshalalfa, Nick Fishbane, Adam B. Weiner, Rohit Mehra, Brandon A. Mahal, Jonathan Lehrer, Yang Liu, Shuang G. Zhao, Corey Speers, Todd M. Morgan, Adam P. Dicker, Stephen J. Freedland, R. Jeffery Karnes, Sheila Weinmann, Elai Davicioni, Ashley E. Ross, Robert B. Den, Paul L. Nguyen, Felix Y. FengTamara L. Lotan, Arul M. Chinnaiyan, Edward M. Schaeffer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint Dive into the research topics of 'Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment Naïve primary prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences